US 11,597,771 B2 · Monoclonal antibody directed to FGFR1

Abstract

The present invention relates to antibodies with specificity for FGFR1. More particularly, the invention relates to monoclonal antibodies that bind specifically to and neutralize human, macaque and mouse forms of FGFR1 with high affinity. The invention also relates to nucleic acids encoding said antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis and/or treatment of cancers.

Claims15

Dependent claims

A monoclonal antibody or portion thereof that binds to FGFR1, which comprises:

a) a heavy chain variable domain comprising H-CDR1, H-CDR2 and H-CDR3, wherein:
i) H-CDR1 comprises SEQ ID NO:
3;
ii) H-CDR2 comprises SEQ ID NO:
4;
iii) H-CDR3 comprises SEQ ID NO:
5;
and
b) a light chain variable domain comprising L-CDR1, L-CDR2 and L-CDR3, wherein:
i) L-CDR1 comprises SEQ ID NO:
18;
ii) L-CDR2 comprises SEQ ID NO:
19;
and
iii) L-CDR3 comprises SEQ ID NO:
20.

13 more elements

Dependencies are inferred from the claim text.

Facts

Application

16/462,961Filed 21 Nov 2017 · us provisional application

Priority

EP 1620030423 Nov 2016

Published

US 2019/0367620 A15 Dec 2019

Granted

7 Mar 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification17 codes

C07K 16/2863
Against receptors, cell surface antigens or cell surface determinants: against receptors for growth factors, growth regulators
A61P 35/00
Antineoplastic agents
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies
C07K 2317/21
Characterized by taxonomic origin: from primates, e.g. man

Monoclonal antibody directed to FGFR1

Life of this patent

Monoclonal antibody directed to FGFR1

Life of this patent

Abstract

Claims15